You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

~ Buy the SAXAGLIPTIN (saxagliptin hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SAXAGLIPTIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Saxagliptin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00121641 ↗ Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise Completed AstraZeneca Phase 3 2005-07-01 The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
NCT00121667 ↗ Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone Completed AstraZeneca Phase 3 2005-08-01 The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone
NCT00295633 ↗ A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone Completed AstraZeneca Phase 3 2006-03-01 The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone
NCT00313313 ↗ A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas Completed AstraZeneca Phase 3 2006-04-01 The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Saxagliptin

Condition Name

Condition Name for Saxagliptin
Intervention Trials
Type 2 Diabetes Mellitus 35
Type 2 Diabetes 30
Diabetes Mellitus, Type 2 17
Diabetes 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Saxagliptin
Intervention Trials
Diabetes Mellitus, Type 2 93
Diabetes Mellitus 87
Glucose Intolerance 5
Diabetes Mellitus, Type 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Saxagliptin

Trials by Country

Trials by Country for Saxagliptin
Location Trials
United States 490
Canada 80
Mexico 69
China 65
India 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Saxagliptin
Location Trials
Texas 35
California 28
Florida 23
Ohio 20
South Carolina 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Saxagliptin

Clinical Trial Phase

Clinical Trial Phase for Saxagliptin
Clinical Trial Phase Trials
Phase 4 39
Phase 3 42
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Saxagliptin
Clinical Trial Phase Trials
Completed 88
Unknown status 19
Recruiting 8
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Saxagliptin

Sponsor Name

Sponsor Name for Saxagliptin
Sponsor Trials
AstraZeneca 72
Bristol-Myers Squibb 17
Shanghai Jiao Tong University School of Medicine 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Saxagliptin
Sponsor Trials
Other 96
Industry 96
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.